McKenney

McKenney v. Purepac Pharmaceutical Co.

Bad Law
167 Cal. App. 4th 72·2008 Cal. App. LEXIS 1465·83 Cal. Rptr. 3d 810
Court of Appeal of CaliforniaSeptember 25, 2008F052606California4,597 words

Opinion

Opinion

Ardaiz, J.

Appellant Carlyne McKenney brought this civil action against respondent Purepac Pharmaceutical Company (Purepac) and other defendants. Appellant alleges that she was injured as a result of using the prescription drug metoclopramide manufactured by Purepac. The superior court sustained Purepac’s demurrer to McKenney’s fourth amended complaint and entered judgment in favor of Purepac. The pleading alleges that metoclopramide is the active ingredient of the brand name drug Reglan, and that Purepac “distributed the generic drug metoclopramide.” It alleges that there were “false and/or misleading statements contained in” Purepac’s labeling of the drug, and that the labeling “substantially understated and downplayed the risks of tardive dyskinesia,” a condition McKenney contracted as a result of her treatment with metoclopramide. The superior court concluded: “All of Plaintiff’s causes against Purepac are pre-empted by federal law. . . . Defendant Purepac is not the original manufacturer of Reglan. It is a generic manufacturer of metoclopramide and, as such, must obtain approval by the FDA before issuing any label [on] metoclopramide which deviates from the labeling previously…

Sign in to read the full opinion

Create a free account to read the complete opinion text, citation history, and good-law status for this case.